Enhua Pharmaceutical Industry (002262.SZ): Sulfobutyl hydrochloride tablets pass the generic drug consistency evaluation.

Zhijian Finance APP News, Enhua Pharmaceutical (002262.SZ) announced that the company recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration (referred to as "NMPA") regarding the approval of the hydrochloride levosulpiride tablet. The drug has been approved through generic drug quality and efficacy consistency evaluation. Hydrochloride levosulpiride tablets are used for chorea, Tourette syndrome, and senile psychosis, and can also be used for ethanol poisoning, etc. The company has invested approximately 5.7 million yuan in research and development expenses for the consistency evaluation project of this product.